Governance Legend Biotech Corporation

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
22.14 ^USD	+0.14%		-6.19%	+1.84%

01-14	Legend Biotech Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:00 AM
01-12	Legend Biotech highlights recent business updates at 44th annual J.P. Morgan Healthcare conference	RE

Executive Committee: Legend Biotech Corporation

Manager

Positions heldSince

Ying Huang

53 year

Chief Executive Officer

20/09/2020

Jim Pepin

General Counsel

31/10/2023

Elaine Qian

Human Resources Officer

Mythili Koneru

48 year

Chief Tech/Sci/R&D Officer

10/04/2023

Tracy Luo

Chief Tech/Sci/R&D Officer

30/04/2018

Guowei Fang

Chief Tech/Sci/R&D Officer

28/02/2022

Jessie Yeung

41 year

Investor Relations Contact

31/12/2018

Yuhong Qiu

General Counsel

30/04/2018

Composition of the Board of Directors: Legend Biotech Corporation

Director

CommitteesSince

Fang Liang Zhang

61 year

Chairman

01/08/2022

Ye Wang

57 year

Compensation Committee	01/08/2022
Nominating Committee	10/03/2025
Audit Committee Chair	28/05/2025
Governance Committee Chair	01/08/2022
Nominating Committee Chair	01/08/2022

Wai Man Yau

50 year

Governance Committee
Nominating Committee
Audit Committee Chair	30/04/2020

Corazon Sanders

69 year

Audit Committee
Compensation Committee

Xiao Hui Ji

64 year

Audit Committee
Compensation Committee Chair	30/04/2020

Patrick Casey

70 year

Governance Committee
Nominating Committee

Tomas Jan Heyman

70 year

Governance Committee

30/05/2023

Li Zhu

76 year

Director/Board Member

22/11/2020

Ying Huang

53 year

Director/Board Member

29/12/2021

Li Mao

69 year

Director/Board Member	01/08/2022
Independent Dir/Board Member	01/08/2022

Peter Salovey

68 year

Director/Board Member	08/08/2024
Independent Dir/Board Member	08/08/2024

Latest Appointments: Legend Biotech Corporation

14/10/25	Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025	CI
18/08/25	Legend Biotech Corporation Announces Chief Financial Officer Changes	CI
18/08/25	Legend Biotech appoints Carlos Santos as chief financial officer	RE
18/08/25	Legend Biotech Names Carlos Santos CFO	MT
18/08/25	Legend Biotech Corporation Appoints Carlos Santos as the Company?s Principal Financial Officer and Principal Accounting Officer, Each Effective as of August 18, 2025	CI
16/06/25	SPIC Yuanda Environmental Protection Names Chief Accountant	MT
05/06/25	Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025	CI

More news

Former Officers and Directors: Legend Biotech Corporation

Insider

Positions held

SinceUntil

Lori Macomber

Comptroller/Controller/Auditor	31/08/2019	29/02/2020
Director of Finance/CFO	08/05/2022	01/01/2025
Corporate Officer/Principal	29/02/2020	08/05/2022

Steven J. Gavel

Corporate Officer/Principal

31/07/2018

31/12/2024

Tina Carter

Public Communications Contact

30/06/2021

30/11/2023

Liz Gosen

Chief Tech/Sci/R&D Officer

30/04/2019

30/11/2023

Marc L. Harrison

General Counsel

31/12/2021

30/06/2023

Lida Pacaud

Chief Tech/Sci/R&D Officer

31/12/2020

31/05/2023

Meeta Chatterjee

Corporate Officer/Principal

28/02/2019

31/10/2022

Robert Sexton

Corporate Officer/Principal

31/03/2019

30/09/2022

Frank Fan

Chief Tech/Sci/R&D Officer	31/12/2013	29/03/2022
Founder	-	29/03/2022

John Tomtishen

Corporate Officer/Principal

10/10/2021

Crystal Chen

Public Communications Contact

31/12/2020

Syed Rizvi

Chief Tech/Sci/R&D Officer

31/05/2018

31/10/2020

Yuan Xu

Director/Board Member	28/02/2018	31/07/2020
Chief Executive Officer	28/02/2018	31/07/2020

Qi Pan

Chief Tech/Sci/R&D Officer

31/07/2017

31/12/2017

Zuie Chin Huang

Founder

Joanne Choi

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	16
Female	3

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	10
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,900

Sector

Biotechnology & Medical Research

Calendar

03-17 - Q4 2025 Earnings Release (Projected)

More about the company